Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ: ATRA )

11.40 +1.47 (+14.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Understanding Atara Biotherapeutics's Unusual Options Activity
On Monday, shares of Atara Biotherapeutics (NASDAQ:ATRA) ... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed
Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a... 
Via Benzinga
Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript
ATRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript
ATRA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.